For citations:
In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved. Cancer Urology. 2019;15(4):140-142. (In Russ.)
Views PDF (Rus): 805
Email this article 